HK Stock MarketDetailed Quotes

06618 JD HEALTH

Watchlist
  • 23.000
  • -0.150-0.65%
Market Closed Sep 13 16:08 CST
73.38BMarket Cap25.58P/E (TTM)

JD HEALTH Key Stats

All
YOY yoy
Hide blank lines yoy
(Q6)Jun 30, 2024
(Q3)Mar 31, 2024
(FY)Dec 31, 2023
(Q6)Jun 30, 2023
(Q3)Mar 31, 2023
(FY)Dec 31, 2022
(Q6)Jun 30, 2022
(FY)Dec 31, 2021
(Q6)Jun 30, 2021
(FY)Dec 31, 2020
Turnover
4.55%28.34B
-4.90%13.27B
14.54%53.53B
34.04%27.11B
--13.95B
52.32%46.74B
48.30%20.23B
58.30%30.68B
55.37%13.64B
78.77%19.38B
Operating income
4.55%28.34B
14.54%53.53B
34.04%27.11B
52.32%46.74B
48.30%20.23B
58.30%30.68B
55.37%13.64B
78.77%19.38B
Cost of sales
-3.52%-21.64B
----
-13.08%-41.66B
-32.24%-20.91B
----
-56.89%-36.84B
-53.05%-15.81B
-62.35%-23.48B
-57.48%-10.33B
-80.14%-14.47B
Operating expenses
-3.52%-21.64B
-13.08%-41.66B
-32.24%-20.91B
-56.89%-36.84B
-53.05%-15.81B
-62.35%-23.48B
-57.48%-10.33B
-80.14%-14.47B
Gross profit
8.01%6.7B
19.95%11.87B
40.51%6.2B
37.43%9.89B
33.47%4.41B
46.37%7.2B
49.15%3.31B
74.85%4.92B
Selling expenses
-17.52%-1.4B
----
-20.91%-2.65B
-28.03%-1.19B
----
-2.90%-2.2B
4.59%-933.3M
-48.74%-2.13B
-79.69%-978.18M
-92.30%-1.43B
Administrative expenses
21.87%-685.06M
----
7.20%-2B
11.09%-876.78M
----
15.12%-2.15B
12.17%-986.16M
-381.25%-2.54B
-1,226.44%-1.12B
-322.01%-527.19M
Research and development expenses
-4.56%-645.02M
----
-14.93%-1.23B
-26.72%-616.86M
----
-19.52%-1.07B
-21.16%-486.8M
-46.60%-892.91M
-44.44%-401.79M
-80.07%-609.07M
Revaluation surplus
----
----
----
----
----
----
----
----
----
-1,288.60%-17.54B
-Changes in the fair value of other assets
----
----
----
----
----
----
----
----
----
-1,288.60%-17.54B
Impairment and provision
116.10%10.41M
----
28.86%-69.86M
-486.50%-64.66M
----
-156.05%-98.2M
-12.15%-11.03M
-32,679.49%-38.35M
-2,161.01%-9.83M
93.71%-117K
-Other impairment is provision
116.10%10.41M
----
28.86%-69.86M
-486.50%-64.66M
----
-156.05%-98.2M
-12.15%-11.03M
-32,679.49%-38.35M
-2,161.01%-9.83M
93.71%-117K
Operating interest expense
----
----
-4.24%-9.49M
----
----
-51.68%-9.1M
-102.28%-4.87M
-75.61%-6M
-38.05%-2.41M
90.38%-3.42M
Special items of operating profit
1.47%-2.48B
----
12.11%-3.14B
-60.77%-2.52B
----
-49.19%-3.58B
-42.77%-1.57B
-33.27%-2.4B
-28.70%-1.1B
-58.11%-1.8B
Operating profit
60.48%1.49B
-38.74%487.32M
248.75%2.76B
118.67%931.36M
795.45M
198.17%792.57M
239.75%425.91M
95.25%-807.33M
94.19%-304.77M
-1,936.07%-17B
Financing income
5.67%989.51M
----
----
--936.46M
----
----
----
----
----
----
Financing cost
8.34%-4.02M
----
----
---4.39M
----
----
----
----
----
----
Share of profits of associates
-26.74%-40.81M
----
26.87%-70.76M
33.70%-32.2M
----
-2.75%-96.76M
-19.82%-48.57M
-22.25%-94.17M
---40.53M
---77.02M
Earning before tax
33.21%2.44B
287.08%2.69B
385.29%1.83B
177.18%695.81M
209.28%377.35M
94.72%-901.49M
93.43%-345.3M
-1,945.30%-17.07B
Tax
-50.41%-404.96M
----
-76.10%-550.47M
-74.39%-269.23M
----
-82.45%-312.58M
-41.76%-154.39M
-5.27%-171.33M
-5.14%-108.91M
-18.71%-162.76M
After-tax profit from continuing operations
30.24%2.03B
459.16%2.14B
600.58%1.56B
135.72%383.23M
149.09%222.96M
93.78%-1.07B
91.53%-454.21M
-1,673.49%-17.23B
Earning after tax
30.24%2.03B
459.16%2.14B
600.58%1.56B
135.72%383.23M
149.09%222.96M
93.78%-1.07B
91.53%-454.21M
-1,673.49%-17.23B
Minority profit
-542.27%-2.8M
----
-66.74%1.04M
206.73%634K
----
353.41%3.12M
-163.80%-594K
229.03%689K
143.04%931K
---534K
Profit attributable to shareholders
30.48%2.04B
463.49%2.14B
598.43%1.56B
135.41%380.11M
149.12%223.55M
93.77%-1.07B
91.51%-455.14M
-1,673.44%-17.23B
Basic earnings per share
30.00%0.65
475.00%0.69
614.29%0.5
134.29%0.12
146.67%0.07
95.51%-0.35
-0.15
-1,633.33%-7.8
Diluted earnings per share
32.65%0.65
466.67%0.68
600.00%0.49
134.29%0.12
146.67%0.07
95.51%-0.35
-0.15
-1,633.33%-7.8
Currency Unit
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
Accounting Standards
IAS
IAS
IAS
IAS
IAS
IAS
IAS
IAS
IAS
IAS
Audit Opinions
--
--
Unqualified Opinion
--
--
Unqualified Opinion
--
Unqualified Opinion
--
Unqualified Opinion
Auditor
--
--
Deloitte & Touche Tohmatsu Certified Public Accountants
--
--
Deloitte & Touche Tohmatsu Certified Public Accountants
--
Deloitte & Touche Tohmatsu Certified Public Accountants
--
Deloitte & Touche Tohmatsu Certified Public Accountants
(Q6)Jun 30, 2024(Q3)Mar 31, 2024(FY)Dec 31, 2023(Q6)Jun 30, 2023(Q3)Mar 31, 2023(FY)Dec 31, 2022(Q6)Jun 30, 2022(FY)Dec 31, 2021(Q6)Jun 30, 2021(FY)Dec 31, 2020
Turnover 4.55%28.34B-4.90%13.27B14.54%53.53B34.04%27.11B--13.95B52.32%46.74B48.30%20.23B58.30%30.68B55.37%13.64B78.77%19.38B
Operating income 4.55%28.34B14.54%53.53B34.04%27.11B52.32%46.74B48.30%20.23B58.30%30.68B55.37%13.64B78.77%19.38B
Cost of sales -3.52%-21.64B-----13.08%-41.66B-32.24%-20.91B-----56.89%-36.84B-53.05%-15.81B-62.35%-23.48B-57.48%-10.33B-80.14%-14.47B
Operating expenses -3.52%-21.64B-13.08%-41.66B-32.24%-20.91B-56.89%-36.84B-53.05%-15.81B-62.35%-23.48B-57.48%-10.33B-80.14%-14.47B
Gross profit 8.01%6.7B19.95%11.87B40.51%6.2B37.43%9.89B33.47%4.41B46.37%7.2B49.15%3.31B74.85%4.92B
Selling expenses -17.52%-1.4B-----20.91%-2.65B-28.03%-1.19B-----2.90%-2.2B4.59%-933.3M-48.74%-2.13B-79.69%-978.18M-92.30%-1.43B
Administrative expenses 21.87%-685.06M----7.20%-2B11.09%-876.78M----15.12%-2.15B12.17%-986.16M-381.25%-2.54B-1,226.44%-1.12B-322.01%-527.19M
Research and development expenses -4.56%-645.02M-----14.93%-1.23B-26.72%-616.86M-----19.52%-1.07B-21.16%-486.8M-46.60%-892.91M-44.44%-401.79M-80.07%-609.07M
Revaluation surplus -------------------------------------1,288.60%-17.54B
-Changes in the fair value of other assets -------------------------------------1,288.60%-17.54B
Impairment and provision 116.10%10.41M----28.86%-69.86M-486.50%-64.66M-----156.05%-98.2M-12.15%-11.03M-32,679.49%-38.35M-2,161.01%-9.83M93.71%-117K
-Other impairment is provision 116.10%10.41M----28.86%-69.86M-486.50%-64.66M-----156.05%-98.2M-12.15%-11.03M-32,679.49%-38.35M-2,161.01%-9.83M93.71%-117K
Operating interest expense ---------4.24%-9.49M---------51.68%-9.1M-102.28%-4.87M-75.61%-6M-38.05%-2.41M90.38%-3.42M
Special items of operating profit 1.47%-2.48B----12.11%-3.14B-60.77%-2.52B-----49.19%-3.58B-42.77%-1.57B-33.27%-2.4B-28.70%-1.1B-58.11%-1.8B
Operating profit 60.48%1.49B-38.74%487.32M248.75%2.76B118.67%931.36M795.45M198.17%792.57M239.75%425.91M95.25%-807.33M94.19%-304.77M-1,936.07%-17B
Financing income 5.67%989.51M----------936.46M------------------------
Financing cost 8.34%-4.02M-----------4.39M------------------------
Share of profits of associates -26.74%-40.81M----26.87%-70.76M33.70%-32.2M-----2.75%-96.76M-19.82%-48.57M-22.25%-94.17M---40.53M---77.02M
Earning before tax 33.21%2.44B287.08%2.69B385.29%1.83B177.18%695.81M209.28%377.35M94.72%-901.49M93.43%-345.3M-1,945.30%-17.07B
Tax -50.41%-404.96M-----76.10%-550.47M-74.39%-269.23M-----82.45%-312.58M-41.76%-154.39M-5.27%-171.33M-5.14%-108.91M-18.71%-162.76M
After-tax profit from continuing operations 30.24%2.03B459.16%2.14B600.58%1.56B135.72%383.23M149.09%222.96M93.78%-1.07B91.53%-454.21M-1,673.49%-17.23B
Earning after tax 30.24%2.03B459.16%2.14B600.58%1.56B135.72%383.23M149.09%222.96M93.78%-1.07B91.53%-454.21M-1,673.49%-17.23B
Minority profit -542.27%-2.8M-----66.74%1.04M206.73%634K----353.41%3.12M-163.80%-594K229.03%689K143.04%931K---534K
Profit attributable to shareholders 30.48%2.04B463.49%2.14B598.43%1.56B135.41%380.11M149.12%223.55M93.77%-1.07B91.51%-455.14M-1,673.44%-17.23B
Basic earnings per share 30.00%0.65475.00%0.69614.29%0.5134.29%0.12146.67%0.0795.51%-0.35-0.15-1,633.33%-7.8
Diluted earnings per share 32.65%0.65466.67%0.68600.00%0.49134.29%0.12146.67%0.0795.51%-0.35-0.15-1,633.33%-7.8
Currency Unit CNYCNYCNYCNYCNYCNYCNYCNYCNYCNY
Accounting Standards IASIASIASIASIASIASIASIASIASIAS
Audit Opinions ----Unqualified Opinion----Unqualified Opinion--Unqualified Opinion--Unqualified Opinion
Auditor ----Deloitte & Touche Tohmatsu Certified Public Accountants----Deloitte & Touche Tohmatsu Certified Public Accountants--Deloitte & Touche Tohmatsu Certified Public Accountants--Deloitte & Touche Tohmatsu Certified Public Accountants

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
HK
Overall
Symbol
Latest Price
% Chg

No Data